Microrna Liquid Biopsy
Microrna Liquid Biopsy - Related Videos
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
0 Views •
Cited by 3 •
2022
The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.
01:22
MicroRNAs
0 Views •
2019
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
0 Views •
Cited by 34 •
2017
Here, we present the detailed protocol adopted in the BioMILD screening trial to perform the circulating microRNA signature classifier test for early lung cancer detection.
06:04
Aqueous Humor as a Liquid Biopsy for Retinoblastoma: Clear Corneal Paracentesis and Genomic Analysis
0 Views •
Cited by 36 •
2021
The aqueous humor is a high-yield liquid biopsy for retinoblastoma, intraocular cancer that cannot be biopsied in vivo due to the risk of extraocular spread. Herein, a method for safely extracting aqueous humor via clear corneal paracentesis and steps for genomic analysis to identify prognostic biomarkers are presented.
08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
0 Views •
Cited by 59 •
2016
This protocol describes the feasibility to perform miRNA profiling in exosomes, released in plasma of NSCLC patients, through a commercial exosome isolation kit with Proteinase K and RNAse treatments, in order to avoid circulating miRNAs contamination and evaluate their biomarker features in NSCLC.
FAQs
Protection from degradation is central to the analytical value of circulating microRNAs. Tumor and surrounding cells package these molecules in extracellular vesicles, including exosomes, or associate them with protein complexes. These forms help preserve microRNAs in blood and other body fluids, allowing researchers to measure disease-associated expression patterns rather than losing the signal before analysis.
Distinct expression patterns can provide molecular information about cancer even when researchers do not repeatedly sample tumor tissue. By profiling circulating microRNAs, investigators can search for signals associated with cancer presence, tumor classification, prognosis, or changes relevant to treatment monitoring. This makes the pattern itself an important basis for biomarker discovery and cancer-focused analysis.
Its main distinction is the sample source and invasiveness. Instead of relying exclusively on tissue obtained through repeated sampling, researchers analyze microRNAs present in blood or other body fluids. This minimally invasive approach can provide cancer-related molecular information while reducing dependence on repeated tissue collection, supporting research situations in which ongoing or additional tumor sampling is undesirable.
The workflow begins with collecting a blood or other biofluid sample. Researchers then isolate the circulating microRNAs, including molecules carried in extracellular vesicles or protein complexes, and profile them with quantitative PCR or sequencing. The resulting measurements are examined for disease-associated expression patterns that may support biomarker discovery or other cancer research objectives.
The approach can contribute to biomarker discovery, early detection, tumor classification, prognosis, and treatment monitoring. These applications depend on identifying and interpreting cancer-associated microRNA expression patterns in collected biofluid samples. Because one method can address several research questions, investigators may use it to study both the presence and clinically relevant characteristics of cancer.
MicroRNA liquid biopsy can provide molecular information from a minimally invasive sample, helping researchers investigate patterns related to tumor characteristics, prognosis, and treatment monitoring. In this context, the method supports the search for patient-relevant biomarkers and may help establish a foundation for more personalized cancer care, although the overview frames this as a potential research direction.